Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis

BACKGROUND: Patients with multiple sclerosis (pwMS) are often treated with disease modifying therapies (DMT) with immunomodulatory effects. This is of particular concern following the development of several vaccines to combat coronavirus disease 19 (COVD-19), a potentially fatal illness caused by SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyang, Tirisham V., Evans, John P., Miller, Joseph S., Alcorn, Kariss, Peng, Juan, Bell, Erica H., Zeng, Cong, Gumina, Richard, Liu, Shan-Lu, Segal, Benjamin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941285/
https://www.ncbi.nlm.nih.gov/pubmed/35342640
http://dx.doi.org/10.1177/20552173221087357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941285/
https://www.ncbi.nlm.nih.gov/pubmed/35342640
http://dx.doi.org/10.1177/20552173221087357

Ejemplares similares